10x Genomics (TXG) Price & Analysis

Compare

1,218 Followers

TXG Stock Chart & Stats

$19.99

-$0.12(-0.77%)

At close: Jan 08 4:00 PM EST

$19.99

-$0.12(-0.77%)

Day’s Range― - ―

52-Week Range$6.78 - $20.34

Previous CloseN/A

Volume385.49K

Average Volume (3M)1.86M

Market Cap

$2.53B

Enterprise Value$1.12B

Total Cash (Recent Filing)$482.08M

Total Debt (Recent Filing)$86.98M

Price to Earnings (P/E)―

Beta1.40

Next Earnings

Feb 18, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding116,474,180

10 Day Avg. Volume1,458,383

30 Day Avg. Volume1,860,371

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)2.44

Price to Sales (P/S)2.83

P/FCF Ratio-301.92

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue1.75

Enterprise Value/Gross Profit2.54

Enterprise Value/Ebitda-36.41

Forecast

1Y Price Target

$17.89

Price Target Upside-10.51% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet And PositioningA strong balance sheet combined with leading products supports execution through a muted market environment and underpins analyst buy-side interest.

Consumables GrowthXenium and spatial consumables are delivering nearly 20% year-over-year growth, supported by higher average runs and steady single-cell reaction demand that can drive recurring revenue.

Product Launches And AdoptionIntroductions of next-generation Chromium Flex and Xenium Protein are accelerating new kit adoption and reinforcing the firm's competitive product portfolio.

Bears Say

Competitive Pressure And VisibilityIncreased competitive risks and ongoing macro uncertainty are disrupting customer purchasing patterns and reducing visibility into future sales.

Revenue Trend WeaknessReported revenue declines, including a 4% year-over-year drop and weaker year-to-date trends, highlight slower recovery in core markets.

US Academic And Government DemandPersistent weakness in US academic and government (A&G) demand is suppressing order activity and could prolong pressure on top-line momentum.

10x Genomics News

10x Genomics price target raised to $18 from $15 at TD Cowen

TD Cowen analyst Dan Brennan raised the firm’s price target on 10x Genomics (TXG) to $18 from $15...

2d ago

TXG

10x Genomics price target raised to $20 from $19 at Canaccord

Canaccord raised the firm’s price target on 10x Genomics (TXG) to $20 from $19 and keeps a Buy...

18d ago

TXG

10x Genomics price target raised to $18 from $15 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on 10x Genomics (TXG) to $18 from $15 and...

25d ago

TXG

10x Genomics price target raised to $22 from $17 at Barclays

Barclays raised the firm’s price target on 10x Genomics (TXG) to $22 from $17 and keeps an Overweight...

25d ago

TXG

10x Genomics downgraded to Neutral from Buy at Citi

Citi downgraded 10x Genomics (TXG) to Neutral from Buy with an unchanged price target of $18. The firm...

29d ago

TXG

Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

ALB

10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh downgraded 10x Genomics (TXG) to Equal Weight from Overweight with a price target...

1M ago

TXG

10x Genomics downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded 10x Genomics (TXG) to Equal Weight from Overweight with a price target of $20, up...

1M ago

TXG

10x Genomics Announces Chief Legal Officer Retirement

10x Genomics ( ($TXG) ) has provided an update. On November 12, 2025, Eric S. Whitaker announced his...

2M ago

TXG

10x Genomics price target raised to $19 from $15 at Piper Sandler

Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $19 from $15 and keeps a...

2M ago

TXG

10X Genomics Earnings Call: Mixed Results Amid Challenges

10X Genomics (($TXG)) has held its Q3 earnings call. Read on for the main highlights of the call....

2M ago

TXG

Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 6, according to daily fund...

2M ago

TER

TXG

10x Genomics: Balancing Growth Potential with Macroeconomic Challenges – Hold Rating Maintained

William Blair analyst Matt Larew has maintained their neutral stance on TXG stock, giving a Hold rating today....

2M ago

TXG

10x Genomics price target raised to $14 from $13 at UBS

UBS raised the firm’s price target on 10x Genomics (TXG) to $14 from $13 and keeps a Neutral...

2M ago

TXG

TXG FAQ

What was 10x Genomics Inc’s price range in the past 12 months?

10x Genomics Inc lowest stock price was $6.78 and its highest was $20.34 in the past 12 months.

What is 10x Genomics Inc’s market cap?

10x Genomics Inc’s market cap is $2.53B.

When is 10x Genomics Inc’s upcoming earnings report date?

10x Genomics Inc’s upcoming earnings report date is Feb 18, 2026 which is in 40 days.

How were 10x Genomics Inc’s earnings last quarter?

10x Genomics Inc released its earnings results on Nov 06, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.068.

Is 10x Genomics Inc overvalued?

According to Wall Street analysts 10x Genomics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 10x Genomics Inc pay dividends?

10x Genomics Inc does not currently pay dividends.

What is 10x Genomics Inc’s EPS estimate?

10x Genomics Inc’s EPS estimate is -0.22.

How many shares outstanding does 10x Genomics Inc have?

10x Genomics Inc has 116,474,180 shares outstanding.

What happened to 10x Genomics Inc’s price movement after its last earnings report?

10x Genomics Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 17.308%.

Which hedge fund is a major shareholder of 10x Genomics Inc?

Currently, no hedge funds are holding shares in TXG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

10x Genomics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-10.12%

Trailing 12-Months

Asset Growth

9.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

10x Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics (TXG) Earnings & Revenues

Historic Earnings Reports

TXG Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture, with strong performance in spatial consumables and successful new product launches offset by declines in overall revenue and instrument sales. Ongoing macroeconomic challenges and funding uncertainties continue to pose challenges.View all TXG earnings summaries

TXG Revenue Breakdown

60.32% Americas

22.99% EMEA

8.45% Asia-Pacific excluding China

8.24% China

TXG Stock 12 Month Forecast

Average Price Target

$17.89

▼(-10.51% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","11":"$11","15":"$15","19":"$19","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11,15,19,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,16.747692307692308,17.185384615384613,17.623076923076923,18.06076923076923,18.498461538461537,18.936153846153847,19.373846153846152,19.81153846153846,20.24923076923077,20.686923076923076,21.124615384615385,21.56230769230769,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,16.43153846153846,16.553076923076922,16.674615384615382,16.796153846153846,16.917692307692306,17.03923076923077,17.16076923076923,17.282307692307693,17.403846153846153,17.525384615384617,17.646923076923077,17.768461538461537,{"y":17.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,16.13230769230769,15.954615384615384,15.776923076923076,15.599230769230768,15.42153846153846,15.243846153846153,15.066153846153846,14.888461538461538,14.71076923076923,14.533076923076923,14.355384615384615,14.177692307692308,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.08,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >